Tech Company Financing Transactions
Neurovance Funding Round
On 4/1/2014, Neurovance raised $6.3 million in Series A investment from GBS Venture Partners, H&Q Asia/Pacific and Novartis Venture Fund.
Transaction Overview
Company Name
Announced On
4/1/2014
Transaction Type
Venture Equity
Venture Equity
Venture Equity
Amount
$6,300,000
Round
Series A
Investors
Proceeds Purpose
This additional commitment to Neurovance reflects our continued belief in EB-1020 SR's potential to be an effective treatment option, initially for adult ADHD, and then possibly for adolescents and children.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
43 Thorndike Street S1-3
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Website
Email Address
Overview
Neurovance is a clinical stage neuroscience-focused company. Following development of centanafadine SR (formerly EB-1020 SR) for adult ADHD, Neurovance will develop centanafadine SR for adolescent and pediatric ADHD.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anthony McKinney
Chief Financial Officer
Gregg Beloff
Chief Medical Officer
Ross Reife
VP - Finance
Vincent Pappafotopoulos
VP - Operations
Catherine O'Brien
Browse more venture capital transactions:
Prev: 4/1/2014: Up My Game venture capital transaction
Next: 4/1/2014: Providence Medical Technology venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs